We excluded 2 approvals from designing RCTs with PFS endpoints: vismodegib for advanced or metastatic basal cell carcinoma (lack of control arm) and entrectinib for metastatic neutropenic tyrosine receptor kinase solid tumors (PFS in the reported SAS was notably shorter than that reported with the existing standard of care) (10). Here, NTRK1 is linked to basal cell carcinoma.